Exercise capacity and N-terminal pro-brain natriuretic peptide levels with biventricular vs. right ventricular pacing for atrioventricular block: results from the PREVENT-HF German Substudy
Open Access
- 16 July 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 16 (1) , 63-70
Abstract
Previous studies showed unfavourable effects of right ventricular (RV) pacing. Ventricular pacing (VP), however, is required in many patients with atrioventricular (AV) block. The PREVENT-HF study explored left ventricular (LV) remodelling during RV vs. biventricular (BIV) pacing in AV block without advanced heart failure. The pre-specified PREVENT-HF German Substudy examined exercise capacity and N-terminal pro-brain natriuretic peptide (NT-proBNP). Patients with expected VP ≥80% were randomized to RV or BIV pacing. Endpoints were peak oxygen uptake (pVO2), oxygen uptake at the anaerobic threshold (VO2AT), ventilatory efficiency (VE/VCO2), and logNT-proBNP. Considering crossover, intention to treat (ITT), and on-treatment (OT) analyses of covariance (ANCOVA) were performed. For exercise testing 44 (RV: 25, BIV: 19), and for NT-proBNP 53 patients (RV: 29, BIV: 24) were included. The ITT analysis revealed significant differences in pVO2 [ANCOVA effect 2.83 mL/kg/min, confidence interval (CI) 0.83–4.91, P = 0.007], VO2AT (ANCOVA effect 2.14 mL/min/k, CI 0.14–4.15, P = 0.03), and VE/VCO2 (ANCOVA effect −5.46, CI −10.79 to −0.13, P = 0.04) favouring BIV randomization. The significant advantage in pVO2 persisted in OT analysis, while VO2AT and VE/VCO2 showed trends favouring BIV pacing. LogNT-proBNP did not differ between groups. (ITT: ANCOVA effect 0.008, CI –0.40 to +0.41, P = 0.97; OT: ANCOVA effect –0.03, CI −0.44 to 0.30, P = 0.90). Our study suggests that BIV pacing produces better exercise capacity over 1 year compared with RV pacing in patients without advanced heart failure and AV block. In contrast, we observed no significant changes of NT-proBNP. Larger trials will allow appraising the clinical usefulness of BIV pacing in AV block. ClinicalTrials.gov Identifier: NCT00170326Keywords
This publication has 34 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failureAmerican Heart Journal, 2010
- Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure: Prognostic Comparison from Peak VO2 and VE/VCO2 SlopeThe Open Cardiovascular Medicine Journal, 2010
- Biventricular pacing improves cardiac function and prevents further left atrial remodeling in patients with symptomatic atrial fibrillation after atrioventricular node ablationAmerican Heart Journal, 2010
- Biventricular Pacing in Patients with Bradycardia and Normal Ejection FractionNew England Journal of Medicine, 2009
- Biventricular pacing preserves left ventricular performance in patients with high-grade atrio-ventricular block: a randomized comparison with DDD(R) pacing in 50 consecutive patientsEP Europace, 2008
- Minimizing Ventricular Pacing to Reduce Atrial Fibrillation in Sinus-Node DiseaseNew England Journal of Medicine, 2007
- Adverse Effect of Ventricular Pacing on Heart Failure and Atrial Fibrillation Among Patients With Normal Baseline QRS Duration in a Clinical Trial of Pacemaker Therapy for Sinus Node DysfunctionCirculation, 2003
- Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure.Circulation, 1982
- Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular diseaseAmerican Heart Journal, 1973